The Use of Fibrin Sealant in the Prevention of Seromas
- 1 March 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 99 (3) , 842-848
- https://doi.org/10.1097/00006534-199703000-00034
Abstract
Seroma formation is a difficult problem to treat and prevent. Its sequelae include wound infection, dehiscence, and skin-flap necrosis. The purpose of this study was to determine the effects of fibrin sealant on seroma formation and wound healing. Seromas were created in a rat model by harvesting the latissimus dorsi muscle. In group I (n = 20), only the latissimus dorsi muscle was harvested. In group II(n = 20), the latissimus dorsi muscle was harvested and fibrin sealant applied. Seromas were routinely aspirated. In group III(n = 20), the latissimus dorsi muscle was harvested, and once a seroma was evident clinically, it was aspirated and injected with fibrin sealant. Fibrin sealant was created by combining virally deactivated fibrinogen and thrombin (American Red Cross, Rockville, Md.). In group I, 90 percent of the animals formed seromas compared with only 20 percent in group II. The average total fluid aspirated in group I was 21 cc versus 6 cc in group II. Sixty percent of the animals in group I and 5 percent in group II required serial drainage for chronic seromas. Skin-flap necrosis occurred in 80 percent of the animals in group I, in 10 percent of group II, and in 40 percent of group III. Histologic evaluation confirmed that group II underwent better wound healing. At necropsy, group I animals with seromas had gross capsular formation; this was not readily apparent in the fibrin sealant groups. We conclude that (1) the harvesting of the rat latissimus dorsi muscle is a reliable model for creating seromas, (2) fibrin sealant effectively prevents seroma formation when applied intraoperatively, (3) wound healing in the seroma rat model is improved with intraoperative fibrin sealant application, (4) closed injection of fibrin sealant for existing seromas cannot be recommended at this time, (5) virally deactivated fibrin sealant retains its hemostatic and adhesive properties, and (6) current clinical trials of virally deactivated fibrin sealant may facilitate its use in the United States. (Plast. Reconstr. Surg. 99: 842, 1997.)Keywords
This publication has 17 references indexed in Scilit:
- Face lifts and sprayed fibrin glue: an outcome analysis of 200 patientsBritish Journal of Plastic Surgery, 1994
- Current status of surgical adhesivesJournal of Surgical Research, 1990
- DRAINAGE OF SEROMAS AFTER LATISSIMUS DORSI MYOCUTANEOUS FLAP BREAST RECONSTRUCTIONPublished by Wolters Kluwer Health ,1989
- Mechanical strength in rat skin incisional wounds treated with fibrin sealantJournal of Surgical Research, 1987
- Evaluation of Fibrin Glue in Rat Sciatic Nerve RepairsPlastic and Reconstructive Surgery, 1986
- Fibrin seal: The state of the artJournal of Oral and Maxillofacial Surgery, 1985
- Use of Fibrin Glue in Thoracic SurgeryThe Annals of Thoracic Surgery, 1985
- Complications of Breast ReconstructionClinics in Plastic Surgery, 1984
- Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patientsCancer, 1983
- Ueber Wirkungen des FibrinsDeutsche Medizinische Wochenschrift (1946), 1909